Tvardi Therapeutics Company Description

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.

The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage.

Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Tvardi Therapeutics, Inc.

Country	United States
Founded	2017
Industry	Biological Products, Except Diagnostic Substances
Employees	12
CEO	Imran Alibhai

Contact Details

Address: 3 Sugar Creek Center Boulevard Sugar Land, Delaware 77478 United States
Phone	713 489 8654
Website	tvarditherapeutics.com

Stock Details

Ticker Symbol	69C
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Imran Alibhai	Chief Executive Officer
Dan Conn	Chief Financial Officer